Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No clinical trials have been registered for SIN3A-related intellectual disability syndrome due to a point mutation.
3 publications have been identified in PubMed for SIN3A-related intellectual disability syndrome due to a point mutation. Research spans Review / Meta-Analysis (33%), Basic Science / Preclinical (33%), and Epidemiology / Natural History (33%).
Gabriel GC (2025). [PMID: 39774941](https://pubmed.ncbi.nlm.nih.gov/39774941/). *Nat Commun*. [Basic Science / Preclinical]
Ota VK (2025). [PMID: 40018685](https://pubmed.ncbi.nlm.nih.gov/40018685/). *Front Psychiatry*. [Epidemiology / Natural History]
Dominguez G (2024). [PMID: 39766920](https://pubmed.ncbi.nlm.nih.gov/39766920/). *Genes (Basel)*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:44 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about SIN3A-related intellectual disability syndrome due to a point mutation